Elevated anxiety-like behavior following ethanol exposure in mutant mice lacking neuropeptide Y (NPY) by Sparta, Dennis R. et al.
Elevated anxiety-like behavior following ethanol exposure in
mutant mice lacking neuropeptide Y (NPY)
Dennis R. Spartaa, Jon R. Feea, Darin J. Knappb,c, George R. Breeseb,c,d, and Todd E.
Thielea,b,*
aFrom the Department of Psychology, University of North Carolina, Chapel Hill, North Carolina,
27599-3270, USA.
bBowles Center for Alcohol Studies, University of North Carolina, Chapel Hill, North Carolina,
27599-7178, USA.
cDepartment of Psychiatry, University of North Carolina, Chapel Hill, North Carolina, 27599-7160,
USA.
dDepartment of Pharmacology, University of North Carolina, Chapel Hill, North Carolina,
27599-7365, USA.
Abstract
Background—Neuropeptide Y (NPY) is a neuromodulator with anxiolytic properties. Recent
evidence suggests that NPY modulates neurobiological responses to ethanol. Because withdrawal
from ethanol is associated with elevated anxiety-like behavior, and because central NPY modulates
anxiety, we assessed anxiety-like behavior in mutant mice lacking normal production of NPY (NPY
−/−) and in normal wild-type mice (NPY+/+) 6-hours after removal of a liquid diet containing 4.5%
ethanol.
Methods—NPY−/− and NPY+/+ mice on a pure 129/SvEv genetic background were given 6-days
of access to a liquid ethanol diet (ED) or control diet (CD). Six-hours before elevated plus maze
(EPM) testing, ED was replaced with CD in the ethanol withdrawn group.
Results—Ethanol withdrawn NPY−/− mice showed significantly less open arm time and total
proportion of time spent in the open arm of the EPM relative to ethanol-withdrawn NPY+/+ mice
and when compared to NPY−/− and NPY+/+ mice that had access to the CD. On the other hand,
ethanol withdrawn NPY+/+ mice did not show altered EPM behavior relative to controls.
Conclusions—Central NPY is protective against anxiety-like behavior stemming from exposure
to and/or withdrawal from ethanol. Targets aimed at NPY receptors may be useful compounds for
treating anxiety associated with ethanol dependence.
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1. Introduction
Factors that may contribute to the initiation of ethanol consumption and/or continued use of
this drug are high basal levels of anxiety and increased anxiety associated with ethanol
withdrawal (Bibb and Chambless, 1986; Breese et al., 2005; Cappell and Herman, 1972;
Cornelius et al., 2003; Koob, 2003; Schuckit and Hesselbrock, 1994). Viewed this way,
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excessive ethanol consumption and relapse drinking results from an attempt to self-medicate
against the negative emotional responses that accompany ethanol withdrawal. Thus,
identifying the neurochemical substrates that modulate withdrawal-induced anxiety may reveal
pharmacological targets for treating alcohol abuse and relapse.
An interesting candidate is neuropeptide Y (NPY), a 36-amino-acid neuromodulator belonging
to the PP-fold family of peptides (Berglund et al., 2003; Colmer and Wahlestedt, 1993; Dumont
et al., 1992) that is expressed throughout the central nervous system (Gray and Morley,
1986) and has been shown to modulate neurobiological responses to ethanol (Badia-Elder et
al., 2001; Pandey et al., 2003a; Thiele et al., 2002; Thiele et al., 1998; Thiele et al., 2004).
There are several observations that make NPY a likely candidate for modulating withdrawal-
induced anxiety. First, NPY possesses anxiolytic properties when infused into the brain (Heilig
et al., 1993; Heilig et al., 1989). Second, twenty-four hours after withdrawal from an ethanol-
containing diet, rats show decreased NPY immunoreactivity in several brain regions including
the central and medial nuclei of the amygdala (Roy and Pandey, 2002). Third, infusion of a
protein kinase A (PKA) activator into the central nucleus of the amygdala, a treatment that
causes increases of amygdalar NPY levels (Pandey et al., 2005), protects against withdrawal-
induced anxiety in rats (Pandey et al., 2003b). The purpose of the present experiment was to
use a genetic approach to study the role of NPY in modulating anxiety-like behavior stemming
from exposure to and/or withdrawal from ethanol using mutant mice lacking production of
NPY (NPY−/−) and normal wild-type mice (NPY+/+).
2. Material and methods
Male and female NPY−/− and littermate NPY +/+ mice were maintained on an inbred pure
129/SvEv background and were developed as described elsewhere (Erickson et al., 1996).
Because there were no significant differences between male and female mice, data are collapsed
across sex within each of the analyses below. All mice were individually housed in plastic
mouse cages with free access to standard rodent chow (Teklad, Madison, WI) and water except
were noted. Mice were approximately 16 weeks of age at the start of each experiment. The
colony room was maintained at approximately 22° C with a 12-hour light/dark cycle and lights
off at 6:00 a.m. All procedures used in the present studies were in compliance with the National
Institute of Health guidelines, and all procedures were approved by the University of North
Carolina Institutional Animal Care and Use Committee (IACUC).
The diet used was a lactalbumin/dextrose-based, nutritionally complete diet with
concentrations of vitamins, minerals and other nutrients derived from ICN Research Diets
(Moy et al., 1997; Moy et al., 2000). Dextrose calories in the control diet (CD) were equated
with ethanol calories in the ethanol diet (ED, 4.5%, w/v). Normal rodent chow was removed
from the mouse cages during access to diet and water was provided in a second bottle. To
reduce spillage, diet was presented to the mice in drinking bottles fitted with ball-point sipper
tubes. Mice were first habituated with 3-days of access to CD and were given 6-days access
to ED (NPY−/−, n = 7; NPY+/+, n = 8) or CD (NPY−/−, n = 8; NPY+/+, n = 8). Six-hours
before testing, ED was replaced with CD in the ethanol-withdrawn groups (ED-WD). We chose
to assess anxiety-like behavior 6-hours after removal of ethanol because we have found
withdrawal-induced anxiety at this time point using the current diet protocol in rats (Knapp et
al., 2004; Overstreet et al., 2002).
To assess anxiety-like behavior, mice were individually tested using elevated plus maze (EPM)
procedures. Testing began at approximately 9:00 a.m., during the dark cycle. The plus maze
(MED Associates, Inc., St. Albans, Vermont) was positioned in the center of the room directly
below a ceiling-mounted lamp fitted with a single 25-watt red light bulb which provided the
only light for the room. Each mouse was placed onto the center square of the plus maze with
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its nose pointing towards one of the open arms. The 5-min test session was video recorded with
a tripod-mounted camcorder. Sessions were scored by genotype-blind investigators for time
spent (min), and the proportion of total time spent, in the open arm defined as open arm time
divided by total time spent in both arms. An animal was considered to have entered an arm of
the plus maze if all four paws had left the center square. Open and closed arm time was
considered terminated once a single paw was placed back into the center square. To determine
possible group differences in locomotor activity, the total number of arm entries (open and
closed) was also assessed. All data in this report are presented as mean ± S. E. M. We used 2
× 2 (genotype x diet) analyses of variance (ANOVAs) to assess main effects and conducted t-
tests (Winer et al., 1991) for planned comparisons. Significance was accepted at P < 0.05.
3. Results
NPY−/− and NPY+/+ mice that drank ED consumed 15.99 ± 0.72 and 15.13 ± 0.65 g ethanol/
kg per day, respectively. On the day of testing, ED-WD groups (NPY−/−, 22.72 ± 1.13 g; NPY
+/+, 22.78 ± 0.76 g) had similar body weight compared to the CD groups (NPY−/−, 24.62 ±
1.91 g; NPY+/+, 23.71 ± 1.01 g). Figure 1 shows EPM data collected on time spent in open
arms, proportion of time in spent open arms, and total arm entries. ANOVA performed on EPM
data (Figure 1A) revealed a significant main effect of genotype {F(1, 27) = 6.20} on the time
spent in the open arm of the plus maze, while an ANOVA performed on data representing the
proportion of time spent in the open arm (Figure 1B) revealed a significant main effect of
genotype {F(1, 27) = 4.81} and a significant genotype by diet interaction effect {F(1, 27) =
6.57}. While NPY−/− mice that were withdrawn from ethanol (ED-WD) showed significantly
less open arm time and proportion of open arm time relative to NPY−/− mice that drank the
CD, there were no significant differences in anxiety-like behavior between NPY+/+ mice given
CD or ED-WD treatment. Additionally, NPY−/− and NPY+/+ mice showed significant
differences in open arm time and in the proportion of time spent in the open arm following the
ED-WD treatment. However, there were no genotype differences in mice that had access to
the CD. An ANOVA performed on total open arm entry data (Figure 1C) revealed no significant
effects.
4. Discussion
Here we show that a lack of normal NPY production predisposes 129/SvEv mice to increased
anxiety-like behavior stemming from exposure to and/or withdrawal from ethanol. Thus,
ethanol-withdrawn NPY−/− mice showed significantly less open arm time and total proportion
of time spent in the open arm of the EPM relative to ethanol-withdrawn NPY+/+ mice, and
when compared with NPY−/− and NPY+/+ mice that had access to the CD. On the other hand,
ethanol-withdrawn NPY+/+ mice did not show altered EPM behavior relative to controls.
Further, the altered EPM activity resulting from ethanol withdrawal in NPY−/− mice was not
related to changes in locomotor activity as there were no group differences in total arm entries.
Thus, these preliminary observations indicate that NPY−/− mice are more sensitive to the
anxiety-like behavior associated with exposure to and/or withdrawal from ethanol.
In the present study, groups that received continuous access to ethanol diet up to the EPM test
were not employed. It is therefore possible that elevated anxiety-like behavior by the NPY−/
− mice in the ED-WD condition resulted from exposure to ethanol, rather than ethanol
withdrawal per se. While we did not assess blood ethanol concentrations (BECs), a previous
report found that 129/SvJ mice metabolize ethanol at a rate of 1.1 mg/dl/min (Homanics et al.,
1998). At this rate, after 6-hours mice in the present experiment could have metabolized up to
396 mg/dl, a BEC they were unlikely to have exceeded at the time ethanol was removed. Thus,
it is unlikely that increased anxiety-like behavior by the NPY−/− mice was related to the
presence of ethanol in the system at the time of EPM testing. Nonetheless, in the absence of
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BEC data and continuous ethanol access groups, a more conservative conclusion for the present
work is that NPY−/− mice show increased anxiety-like behavior stemming from ethanol
exposure, with the possibility that ethanol withdrawal contributes to this response.
Here, wild-type 129/SvEv mice did not display increased anxiety-like behavior 6-hours
following the removal of ethanol. It is possible that EPM testing at time points greater than 6-
hours following ethanol withdrawal, more days with access to ethanol diet, and/or multiple
cycles of ethanol access and withdrawal (Breese et al., 2004; Knapp et al., 2004; Overstreet et
al., 2002, 2004) may augment anxiety-like behavior in the wild-type mice. Such manipulations
will be the subject of future studies. We predict that NPY−/− mice will continue to show
increased anxiety-like behavior in all cases. Additionally, contrary to a previous observation
(Palmiter et al., 1998), NPY−/− mice in the CD condition did not show increased anxiety-like
behavior relative to NPY+/+ mice. Although the reason for this discrepancy is unclear, different
genetic background of NPY−/− mice in the present study (129/SvEv) and the previous work
(C57BL/6J × 129/SvEv) may account for such differences. In fact, genetic background effects
on ethanol-associated phenotypes in NPY−/− mice have previously been reported (Thiele et
al., 2000).
Because NPY−/− mice lack NPY throughout the central nervous system, we can only speculate
on the brain region(s) in which NPY modulates anxiety-like behavior in NPY−/− mice of the
present study. One candidate region is the amygdala. Infusion of NPY into the amygdala
reduces anxiety-like behavior in rodents (Heilig et al., 1993; Sajdyk et al., 1999). Furthermore,
NPY expression is blunted in the central and medial nuclei the amygdala of rats following
ethanol withdrawal (Roy and Pandey, 2002), and infusion of a protein kinase A (PKA) activator
into the central nucleus of the amygdala, a treatment that causes increases of amygdalar NPY
levels (Pandey et al., 2005), protects against withdrawal-induced anxiety in rats (Pandey et al.,
2003b). These observations provide convincing evidence that low NPY signaling in the
amygdala can modulate withdrawal-induced anxiety-like behavior, and suggest the possibility
that a lack of NPY signaling in the amygdala of NPY−/− mice predisposes these animals to
increased anxiety-like behavior following ethanol exposure and withdrawal.
In conclusion, the present investigation reveals that NPY−/− mice show enhanced anxiety-like
behavior stemming from ethanol exposure and/or withdrawal form ethanol, indicating that
NPY−/− mice are a useful model for studying the role of NPY in modulating ethanol-associated
anxiety-like responses. The present and past (Pandey et al., 2003b; Roy and Pandey, 2002)
observations suggest that targets aimed at NPY receptors may be useful compounds for treating
anxiety associated with ethanol exposure and withdrawal, and thus may be useful for preventing
relapse that is triggered by withdrawal-induced anxiety or anxiety stemming from general life
stressors (Breese et al., 2005). Because quantitative trait locus (QTL) analyses suggest that
there are multiple candidate genes for the modulation of anxiety-like behavior, each revealed
with different testing procedures (e.g., elevated plus maze, open field activity, etc.) (Henderson
et al., 2004; Turri et al., 2001), additional studies are required for a more complete
characterization of withdrawal-induced anxiety-like behavior in NPY−/− mice. Important next
steps also include a characterization of the time course of withdrawal-induced anxiety-like
behavior, identifying the NPY receptors that are involved, determining sensitivity of the present
phenotype to the genetic background of the NPY−/− mice, and identifying the brain regions
in which NPY modulates withdrawal responses in these mice.
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Elevated plus maze performance by NPY−/− and NPY+/+ mice following 6-days of access to
a control diet (CD) or 6-days of access to a 4.5% ethanol diet that was withdrawn and replaced
with CD 6-hours before testing (ED-WD). Data from 5-min test sessions are expressed as time
in seconds (a), the proportion of total time that was spent in the open arm (b), and the total
number of arm entries (c). All values reported are mean ± SEM. *NPY−/− mice in the EDWD
significantly different from all other groups (P < 0.05).
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